Hengrui Pharma(SH:600276) Zheng Quan Shi Bao·2025-08-06 18:28Group 1 - In the first seven months of this year, Jiangsu approved 14 innovative drugs for market, surpassing the total of 13 from the previous year, accounting for nearly 30% of the 49 innovative drugs approved nationwide [1] - The approved innovative drugs target diseases such as tumors, spondyloarthritis, and influenza, with notable products including Suweisituzumab, the first anti-angiogenesis drug for "platinum-resistant" ovarian cancer in China [1] - Heng Rui Medicine has increased its innovation efforts, with R&D investment accounting for 29.4% of sales revenue last year, totaling 46 billion yuan, and over 90 self-innovative products currently in clinical development [1] Group 2 - Jiangsu is promoting industrial R&D innovation while optimizing drug review and approval processes, exemplified by the approval of the first segmented production model antibody-drug conjugate in the country [2] - The segmented production model allows for specialized production management and quality control at different sites, enhancing resource allocation and collaboration within the industry [2] - Jiangsu has established seven national key laboratories in the biopharmaceutical field and has been approved to build the first national technology innovation center in this area, leading to a robust innovation ecosystem [2]